EHA 2016 | How the management of CLL is evolving
George Follows, MA, BM, BCh, PhD, FRCP, FRCPath from Cambridge University Hospitals, Cambridge, UK gives an overview of the session on the evolution of chronic lymphocytic leukemia (CLL) management held at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Dr Follows outlines Dr Paolo Ghia’s presentation on how our understanding of the genetics of CLL is having an impact on clinical practice. He further discusses Prof Stephan Stilgenbauer’s talk on new first-line data and how practice is moving away from chemotherapy and potentially towards a chemo-free era. Dr Follows also talks about the potential of ibrutinib, which has received a licence for first-line treatment in Europe and the US and other novel therapies such as acalabrutinib. He gives an overview of Dr Jeff Jones’ talk on relapsed/refractory CLL and ibrutinib and finally, discusses the insights gained from Dr Brian Koffman’s talk on the patient perspective.
